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Background: There is a need for an adherence measure, to monitor adherence services in clinical practice, which
can distinguish between different types of non-adherence and measure changes over time. In order to be inclusive
of all patients it needs to be able to be administered to both patients and carers and to be suitable for patients
taking multiple medications for a range of clinical conditions. A systematic review found that no adherence
measure met all these criteria. We therefore wished to develop a theory based adherence scale (the DAMS) and
establish its content, face and preliminary construct validity in a primary care population.
Methods: The DAMS (consisting of 6 questions) was developed from theory by a multidisciplinary team and the
questions were initially tested in small patient populations. Further to this, patients were recruited when attending
a General Practice and interviewed using the DAMS and two other validated self-reported adherence measures,
theMorisky-8 and Lu questionnaires. A semi-structured interview was used to explore acceptability and reasons for
differences in responses between the DAMS and the other measures. Descriptive data were generated and
Spearman rank correlation tests were used to identify associations between the DAMS and the other adherence
measures.
Results: One hundred patients completed the DAMS in an average of 1 minute 28 seconds and reported finding it
straightforward to complete. An adherence score could not be calculated for the 4(4%) patients only taking ‘when
required’ medication. Thirty six(37.5%) of the remaining patients reported some non-adherence. Adherence ratings
of the DAMS were significantly associated with levels of self reported adherence on all other measures Spearman
Rho 0.348-0.719, (p < 0.01). Differences in trends could generally be explained by qualitative data.
Conclusion: The DAMS has been developed for routine monitoring of adherence in clinical practice. It was
acceptable to patients taking single or multiple medication and valid when tested against other adherence
measures. However, ‘when required’ medication needs to be excluded. Further tests of the DAMS against objective
measures such as MEMS are in progress and reliability needs to be established. Further investigation of the carers’
version of the DAMS is required.
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The Department of Health (DoH) in England has identi-
fied the need to build informed, comprehensive, primary
care-based medication adherence services which are tai-
lored to patients’ needs [1]. Non-adherence to medica-
tion (i.e. patient’s behaviour not matching agreed
recommendations from the prescriber) is estimated to
affect approximately 30- 50% of patients with chronic
conditions [2]. Non adherence may be intentional (i.e
patients deciding not to take the medication) or unin-
tentional (patients forgetting or being unable to take
their medication). The consequences include a missed
opportunity for treatment effect, poor health outcomes
and increased healthcare costs. For example, it has been
estimated that non-adherence is responsible for 48% of
asthma deaths, an 80% increased risk of death in dia-
betes and a 3.8-fold increased risk of death in the year
following a heart attack [3]. In the United Kingdom
(UK) National Health Service (NHS), medicines are the
biggest expenditure after staff and 71% of the medication
budget is spent in primary care (i.e. community settings).
It is estimated that the current cost of unused or un-
wanted medicines exceeds £300 million annually [4]. A
recent paper that mapped the quality of medicines use
in primary care indicated that an improvement in adher-
ence would be the most significant area to target to im-
prove medicine use [5].
We have identified the need for a self report adherence
measure, which can be used to regularly monitor and
continuously improve the quality of adherence services
[6]. It is a vital tool in applying the Model for Improve-
ment [7] allowing individual clinicians to continuously
assess the effects of changes on adherence at individual
and population levels.
Self report has been considered the method of choice
for measuring non-adherence in clinical practice [8]; it is
cheap, relatively unobtrusive, can be used on all types of
medicines and is able to distinguish between intentional
and unintentional non-adherence (which have different
underlying causes and therefore require different inter-
ventions). Hence a self report adherence measure used
in routine clinical practice is needed, by which adher-
ence could be assessed, an appropriate intervention
instigated, and the effectiveness of the intervention eval-
uated. We think the measure of adherence should have
several characteristics. The measure should be rooted in
a theory that allows interventions to be tailored towards
different types of non-adherence. It would also need be
able to be used repeatedly to track patients’ adherence
over time and in response to interventions. It should,
ideally, be brief and acceptable to patients and be able to
be used across a range of clinical conditions. It would
need to be able to be completed by or in conjunction
with carers where necessary, as it is acknowledged thatthey can have significant roles in medication manage-
ment [9]. After conducting a systematic review [6] we
were unable to find an adherence measure which met all
the above criteria.
Aim
To develop a theory based adherence scale (the Diagnos-
tic Adherence to Medication Scale-DAMS) and establish
its content, face and preliminary construct validity in a
primary care population.
Methods
Development of DAMS
The Diagnostic Adherence to Medication Scale (DAMS)
was developed as a short self-report questionnaire based
on patients’ recall of doses missed or doses taken add-
itionally during a 7 day period (see Additional file 1: ap-
pendix 1). It is designed to measure adherence for all of
patients’ medicines. A team of pharmacists and psychol-
ogists were involved in its development. Questions one
and two seek to obtain a denominator of the amount of
medicine which patients have been prescribed. Question
three seeks to obtain the extent of non-adherence to
medication (i.e. number of missed doses) and question
four seeks to identify the type of non-adherence
(intentionally versus unintentionally missing doses).
Question five seeks to assess overuse of medication (i.e.
taking too many doses) and question six seeks to identify
whether this overuse of medication was intentional or
unintentional. Adherence levels for the DAMS are calcu-
lated based on the amount of medication taken divided
by the amount of medication prescribed. These are
multiplied by 100 to attain the percentage of doses taken
(missed doses would thus provide adherence rate <100%
and extra doses taken would provide an adherence rate
>100%). If patients are taking more than one medicine
the mean adherence level can be calculated to give an
overall level. A carers’ version of the DAMS has been
developed (see Additional file 1: appendix 2) which can
be completed by or in conjunction with carers where
necessary.
Theoretical basis of DAMS
The DAMS is rooted in the accident causation frame-
work [10] (which views non-adherence as predominantly
a system issue rather than one of personal blame [11])
and is designed to routinely monitor adherence in clin-
ical practice and to inform the development and evalu-
ation of interventions. Human error theory can be
applied to non-adherence, allowing us to establish the
underlying factors contributing to individuals not taking
medication and enabling us to find appropriate patient
centred solutions [11]. Non-adherence can be consid-
ered a symptom, rather than a diagnosis and in order to
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necessary to diagnose the cause. Intentional and unin-
tentional non-adherence have different underlying
causes and require different interventions. Therefore the
DAMS has been designed to distinguish between these
two types of non-adherence.
We chose to measure adherence as a continuous scale
to allow the detection and quantification of changes in
adherence levels over time, which will enable use of con-
tinuous quality improvement approaches [7] and the
evaluation of adherence services and interventions. In
addition, a continuous scale can also be converted to a
nominal scale to dichotomise adherent and non-
adherent patients according to a clinically appropriate
predefined cut-off point.
We chose to ask about adherence over the last seven
days so that the DAMS could, if necessary, be used re-
peatedly over relatively short periods of time and meas-
ure change in adherence. It was also felt that asking
about the last seven days would result in less recall pro-
blems than a longer time period.
To reduce the social desirability effect, the questions
of the DAMS are framed in a non-judgemental way to
assure the patients that non-adherence is common and
many patients miss doses at times. The DAMS items
therefore use the framing “People often miss taking
doses of their medicines, for a whole range of reasons.
Thinking of the last 7 days. . .” before asking about the
patient’s own medicine taking behaviour.
In primary care patients are often treated for multiple
conditions. Therefore the DAMS is designed to be gen-
eric rather than disease specific and to be suitable for
patients taking a single medication or multiple medica-
tions for different conditions. The DAMS does not in-
clude timing errors as exact timing is only important for
a small minority of medications.
Ethics approval was obtained from NRES Committee
London prior to the commencement of testing of the
DAMS.
Initial testing of the DAMS
During the development process we tested the DAMS
on a small convenience sample of patients several times.
This was an iterative process of constantly adjusting the
wording to make it clearer and gradually extending the
sample it was tested on. Following this, to test patient
acceptability further we used the DAMS as part of ad-
herence audits in patients taking oral therapy for chronic
myeloid leukaemia (n =32 convenience sample during
outpatient clinics) and a range of primary care patients
(n = 67 random sample) using an existing pharmacy
based service designed to help patients with adherence
difficulties. The latter sample was mostly elderly. Follow-
ing these audits further adjustments were made to makethe DAMS more user friendly; an additional question for
patients who could not remember the names of their
medicines was added. At this stage we then wished to
test the DAMS in a wider primary care population.
Testing the DAMS in a wider primary care population
Sampling
The population was all patients attending a primary care
general practice and their carers where appropriate. The
general practice consisted of two centres for health in
separate locations which incorporated walk in centres as
well as surgeries for regular patients. As this was an ex-
ploratory study, a convenience sample of primary care
patients was recruited. However, the two centres to-
gether serve a diverse range of patients from different
socio-economic backgrounds which we believe to be
representative of primary care patients.
A sample size of 100 patients was chosen to enable us
to explore acceptability and ease of use in a general
practice population.
Inclusion criteria
Patients attending an appointment at the general prac-
tice surgery who were taking at least one prescribed
medication. Carers of patients attending appointments
at the general practice surgery and using prescribed
medication. (All forms of medication were included).
Exclusion criteria
Patients not taking medication; patients who were un-
able to give informed consent, patients not speaking
English and children under the age of eighteen.
Recruitment
Patients were approached in the waiting room of the
general practice surgeries. The researcher explained the
study to them and showed them the information leaflet.
Patients who wished to participate signed a consent
form. This included an additional option for patients to
consent to the researcher viewing their medical records.
If patients did not have the capacity to consent they
were excluded and their carer was asked to participate
instead. In these cases the carer signed the consent form
and medical records were not viewed.
Data Collection
Patients were interviewed in a private room at the
general practice. With consent, the interview was audio
recorded. The researcher interviewed the patient using
the research instruments described below. The questions
were read out to the interviewee in relation to all pre-
scribed medication. The order of administering the three
scales (described in the next section) was alternated be-
tween patients to reduce the potential contamination
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was interviewed where a patient was unable to consent
or where they consented but indicated they would prefer
the carer to answer the questions. If written consent had
been obtained from the patient, the researcher accessed
patients’ medical records in order to obtain a list of the
name and dosage of medications which had been
prescribed.
Instruments
We used three adherence instruments: the DAMS,
Morisky- 8 [12] and that of Lu et al [13] and also a ques-
tionnaire exploring aspects of the acceptability and val-
idity of all the instruments. Selection of these adherence
scales followed a systematic review of adherence scales
[6] and our rationale was:
1) The DAMS is a new self report measure of
adherence which has novel properties that support
the finding of practical solutions to non-adherence
(see the development section above).
2) The Morisky Eight Item Medication Adherence Scale
(Morisky-8) is an adherence measure which has been
previously validated in over 1,000 patients with
hypertension [12] but not with other conditions (see
Additional file 1: appendix 3). The first seven items
are dichotomous and the last contains a Likert scale.
Six of the eight items address general adherence
rather than over a specific time scale and items two
and five address adherence over a fortnight and a
day respectively. The Morisky-8 produces an overall
adherence score which ranges from 1-8, a higher
score indicating a greater extent of adherence.
Respondents can also be classified as low (score 1-5),
medium (score 6-7) or high (score 8) adherers
according to their overall score. The Morisky-8
instrument was excluded if the carer rather than
patient took part in the interview, as no carers’
version is available. We chose this instrument as it
has been developed from a widely used and validated
four item scale [14] as well as being validated itself in
a large sample.
3) Lu et al [13] designed an adherence questionnaire in
which the previous month’s adherence was asked
about in three different ways: frequency (eg none of
the time; a little of the time;. . . all the time),
percentage (0%; 10%; 20% . . . 100%) and rating their
ability to take their medication as prescribed (very
poor; poor; . . . excellent) (see Additional file 1:
appendix 4). The questionnaire has been previously
validated in 156 HIV positive patients. In this study
we asked about medication use in the last 7 days
rather than the last month so that the responses
could be more easily compared with those of theDAMS, although we recognise that altering the
measure in this way may have affected its
psychometric properties. We chose this measure as
it includes different question types which have been
shown to have different levels of validity and it
therefore provided an interesting basis of comparison
with the DAMS.
A semi-structured interview addressed the acceptabil-
ity, face and content validity by asking patients or
carers for feedback on acceptability of the measures
and ease of understanding. Construct validity was also
assessed by exploring reasons for differences in the
responses to the three measures. These included direct
questions about the differences in responses as well as
indirect questions further exploring patient’s medication
taking behaviour.Analysis
Data was entered onto Statistical Package for the Social
Sciences version 15 (SPSS). We investigated acceptability
by identifying time to completion, missing data and
patients’ qualitative comments about the instruments.
We used Spearman rank correlation tests to compare
the extent of adherence between the DAMS and the
other adherence measures. We then investigated differ-
ences in trends between the three instruments and used
the qualitative responses patients gave to the questions
to understand these differences further using content
analysis.Results and discussion
Sample and response
One hundred and sixty four (62%) out of 266 individuals
approached agreed to take part. Of those, 100 (62%)
were currently taking medication or were the carer of
the patient currently taking medication. Forty two (42%)
were male and 58 (58%) were female. In 95 (95%) cases
the patient was interviewed, in four cases (4%) the carer
was interviewed and in one case (1%) both the patient
and carer were interviewed. The range of medicines that
had been prescribed indicated a range of clinical condi-
tions. The number of medicines reported as being taken
by patients is shown in Figure 1.
Of those declining to participate, 59 (58%) gave rea-
sons. The most commonly cited reasons included not
having sufficient English to give consent (n = 16, 25%),
not wishing to move from the waiting area to another
room (n = 9, 15%), being called in for their appointment
before being interviewed and leaving the surgery
straight after (n = 9, 15%) and not feeling well enough
(n = 6, 10%).
number of medicines prescribed
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Figure 1 Number of Medicines that respondents were taking.
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The measures were not time consuming to complete
with the DAMS taking a mean of 1 minute 28 seconds
to complete, the Morisky a mean of 1 minute 18 seconds
and the Lu a mean of 40.2 seconds. There was a signifi-
cant moderate correlation between the number of medi-
cines being taken and the time taken to complete the
DAMS (spearman 0.61, p = 0.01) which suggests it could
take longer than the average time to complete for
patients on a large number of medicines. Patients gener-
ally commented that the questions were straightforward
and easy to answer although there were some difficulties
with individual questions of each of the instruments.
These difficulties and any subsequent missing data var-
ied between instruments and are described below.
DAMS: For four (4%) of patients, we were not able to
calculate an adherence score for DAMS because they
had only been prescribed ‘when required’ medication;
there was therefore no denominator of how much medi-
cation they had been prescribed to take. This is a limita-
tion of the DAMS. Questions one and two enabled adenominator to be calculated in every case where regu-
lar medication was prescribed. In all cases where
patients had missed doses or taken extra medication it
was possible to classify them as intentionally or unin-
tentionally non-adherent. Whilst other studies have
found that patients find it difficult to report a specific
number of doses missed [6], respondents reported find-
ing the DAMS questions easy to complete. As the
DAMS carers’ version was only completed by five
respondents, limited data is available on its acceptabil-
ity. However, no missing data was reported and no pro-
blems were identified.
Morisky-8: In four cases (4%), Morisky-8 was not rele-
vant, as a carer was the respondent and there is no
carers’ version. Excluding these cases, we were able to
calculate a Morisky-8 score and assign an adherence cat-
egory for 83 (86%) of respondents. For the remaining 13
(14%) of respondents this was not possible as one or
more items were missing. The overall volume of missing
data was fairly consistent across items. Some specific
issues were identified with some items which explained
Table 1 Extent of self reported non-adherence according
to the DAMS (n =96, missing data excluded)
Overall level of reported
non-adherence
Intentional
n (%)
Unintentional
n (%)
Total
n (%)*
0% n/a n/a 60 (62.5)
1-9% 3 (3.1) 8 (8.3) 11 (11.5)
10-19% 2 (2.1) 9 (9.4) 11 (11.5)
20-49% 2 (2.1) 5 (5.2) 5 (5.2)
50-99% 3 (3.1) 2(2.1) 6 (6.3)
100 1 (1.1) 2 (2.1) 3 (3)
*Some patients were both intentionally and unintentionally non-adherent.
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home do you sometimes forget to bring along your
medication?) was reported to be irrelevant to one re-
spondent as he was on once daily medication and did
not travel, one respondent was unable to answer ques-
tion five (Did you take your medicine yesterday?) as he
had taken some but not all his medication the day be-
fore, one respondent was unable to answer question six
(When you feel like your condition is under control do
you sometimes stop taking your medicine?) because he
had consulted the doctor about stopping when his con-
dition was under control and was following their advice
and one respondent was unable to answer question
seven (Taking medication is a real inconvenience for
some people. Do you ever feel hassled about sticking to
your treatment plan?) because he had only just started
the medication. Whilst not a cause of missing data,
respondents identified difficulties with other questions
during the qualitative part of the interview. Some
respondents found it difficult to choose a yes or no re-
sponse to question one (Do you sometimes forget to
take your medication?) if they rarely forgot. Some
respondents interpreted question two (People sometimes
miss taking their medication for reasons other than for-
getting. Over the past two weeks were there any days
when you did not take your medicine?) as referring to
both intentional and non intentional non-adherence,
and some only to intentional. Some interviewees found
it difficult to answer question three (Have you ever cut
back or stopped taking your medication because you felt
worse when you took it?) as they reported they had
stopped medication and then told the doctor at the next
appointment. For question six (When you feel like your
condition is under control do you sometimes stop taking
your medication?) some respondents reported that they
stopped taking medication when their condition was
under control as it was a ‘when required’ medication.
This led to false positive results.
Lu: The Lu questionnaire [13] produces three separate
scores for frequency, percentage and rating. Nine (9%) of
patients had missing data for the frequency and nine
(9%) for rating but thirty five (35%) had missing data for
percentages. This large amount of missing data for per-
centages was explained by the qualitative data. Many
respondents reported finding this question difficult to
answer and 35 (35%) were not able to respond with a
percentage. Some respondents reported difficulty under-
standing the frequency question; in some cases this was
because they were taking ‘when required’ medication.
Some respondents described finding the question rating
their ability to take medicines difficult to answer, com-
menting that it was ambiguous, or asking for clarifica-
tion. In some cases respondents reported a discrepancy
between rating and behaviour. For example somerespondents stated that their ability was excellent but
that they had decided not to take the medication.
Verification of self reported prescribed medication with
medication records
As the regular GP practice was combined with a walk in
clinic, medication records were not available for the ma-
jority of patients. Patients’ medication was verified by
medication records in 20 (20%) of cases. In ten (50%) of
these cases the self reported number and dosage of
medication on the DAMS corresponded with medication
records. In a further six cases (30%) the medication
records corresponded with the DAMS apart from ‘when
required’ medication; it is possible that patients were
using previous supplies of ‘when required’ medication
that did not appear on recent records and that patients
did not always state their ‘when required’ medication at
interview. Medication prescribed ‘when required’ could
not be included in the DAMS adherence rating calcula-
tion; therefore in a total of 16 (80%) of cases the adher-
ence score would have been identical whether
medication records or self report was used to identify
prescribed medication. In five (20%) of cases the number
or dose of medication prescribed differed between self
report and medication records.
Reported adherence levels
Self reported adherence levels were examined for each
of the three adherence measures.
DAMS: To calculate a DAMS score a denominator of
the total amount of medication prescribed to be taken in
a week was needed. The two possibilities were either to
use medication records or patients’ self report of medi-
cation prescribed. As described above, medication
records were only available for a small proportion of
patients. In addition, we wished to test the DAMS as a
complete measure of self reported adherence. Therefore
patients’ self report of medication prescribed was used.
The resulting mean levels of self reported adherence
according to the DAMS are shown in Table 1. Of those
reporting missed doses (i.e. less than 100% adherence),
Table 2 Classification of adherence according to
Morisky-8 (n =83, missing data excluded)
Adherence category n (%)
High 21 (25)
Medium 26 (31)
Low 36 (44)
Table 4 % of adherence according to Lu questionnaire
(n =65 missing data excluded)
% adherence n(%)
0 2 (3.1)
10 1 (1.6)
20 0 (0)
30 1 (1.6)
40 0 (0)
50 1 (1.6)
60 1 (1.6)
70 5 (7.8)
80 6 (9.4)
90 13 (20.3)
100 34 (53)
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(69%) reported they were unintentionally missed and
one (3%) reported both intentional and unintentional
non-adherence.
Four patients (4%) had been non-adherent by taking
extra medication. In three cases (75%) this was reported
to be intentional and in the fourth case (25%) both
intentional and unintentional non-adherence were
reported.
Morisky-8: The total Morisky-8 score ranged from 1
to 8 with the mean score being 5.86 (standard deviation
1.82). The number of patients classified as high, medium
and low adherers are shown in Table 2.
Lu: The vast majority of respondents reported taking
medication most or all of the time (See Table 3), taking
their medication over 80% of the time (see Table 4) and
that their ability to take their medication was good-
excellent (Table 5).
Tables 1, 3 and 4 also demonstrate that the DAMS,
LU frequency and Lu percentage were able to detect 0%
adherence. Patients identified that they had been pre-
scribed medication but had not taken any in the last
7 days. In the semi structured interviews patients clari-
fied that they had either stopped the medication, decided
to take a drug holiday or forgotten all doses in the last
7 days. (The Morisky-8 and Lu rating are not designed
to distinguish between low and zero adherence).
Comparisons between measures
Table 6 shows the results of the Spearman rank correl-
ation tests to compare adherence on the DAMS to that
reported on the other adherence measures. As shown in
the table, adherence ratings of the DAMS were moder-
ately to strongly correlated with self reported adherence
on all other measures at the p = 0.01 level.Table 3 Frequency of adherence according to Lu
Questionnaire (n = 87 missing data excluded)
Frequency of medication adherence in last 7 days n (%)
None of the time 4 (4.6)
A little of the time 3 (3.4)
Some of the time 3 (3.4)
A good bit of the time 1 (1.1)
Most of the time 27 (31)
All of the time 49 (56.5)Figure 2 further summarises the adherence levels
obtained by the different adherence measures to allow
comparisons to be made. Whilst only the authors of
Morisky-8 have classified adherence as high, medium or
low; in order to allow easier comparisons between
instruments, for the purposes of this figure only, adher-
ence on all measures was classified as high, medium or
low. When developing this classification for the DAMS
and Lu we followed the Morisky-8 classification. High
was equal to perfect adherence (100%, excellent, taking
medication all the time), medium was very good but not
perfect adherence (80-< 100%, taking medication most of
the time) and all other levels of adherence were classi-
fied as low.
Figure 2 shows that although there were significant
associations between the DAMS and other measures,
there was a trend, when compared to the DAMS, for
higher non-adherence to be reported on the Lu ques-
tionnaire and still higher non-adherence to be reported
on the Morisky- 8 scale. Below we use the findings of
the semi-structured interviews to explain this trend.
Morisky-8 vs DAMS: The majority of differences be-
tween Morisky-8 and DAMS could be explained by
there having been differing adherence levels at different
points in time. The DAMS asks about adherence in the
last seven days whereas one item of the Morisky-8 asksTable 5 Rating of adherence according to Lu
questionnaire (n = 91 missing data excluded)
Adherence rating n(%)
Very poor 2 (2.3)
Poor 2 (2.3)
Fair 4 (4.6)
Good 19 (21.8)
Very good 24 (27.6)
Excellent 36 (41.4)
Table 6 Associations between adherence measures
Instrument Spearman’s Rho P value
Morisky-8 and DAMS 0.472 <0.001
Lu frequency and DAMS 0.719 <0.001
Lu percentage and DAMS 0.546 <0.001
Lu rating and DAMS 0.348 0.001
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14 days and the remaining six items do not specify a
time period.
This explanation of differing adherence levels at differ-
ent points of time was initially seen when analysing low
adherers on the Morisky-8. Whilst respondents report-
ing no missed doses on DAMS were more likely to be
high or medium adherers than low adherers on Mor-
isky-8, 13 (36%) respondents classified as low adherers
on Morisky-8 reported no missed doses on the DAMS.
Seven (54%) of these cases can be fully explained by the
fact that the majority of Morisky-8 questions do not ask
about a specific time period, whereas the DAMS specif-
ically asks about the last seven days. Therefore respon-
dents reported that they had exhibited some non-
adherent behaviours at some point in their lives but not
in the previous seven days. In four further cases (31%)
patients had been non-adherent in the last 14 days and
therefore responded positively to question two of the
Morisky-8 (People sometimes miss taking their medica-
tion for reasons other than forgetting. Over the past two
weeks were there any days when you did not take your
medicine?) but had not been non-adherent in the last
seven days and therefore did not report non adherence
on the DAMS. In three cases (21%) respondents were
able to explain this change in recent adherence due to
having been unwell or on holiday. In one case (8%) an
interviewee responded that they had not taken their80%
90%
100%
go
rie
s
40%
50%
60%
70%
n
ce
 c
at
e
0%
10%
20%
30%
A
dh
er
en
Name of adherence me
Figure 2 Comparison of adherence measures.medication yesterday on question five of the Morisky-8
as it was not prescribed to be taken every day.
Due to the trend of differing adherence at different
time periods observed with low adherers, a further ana-
lysis was done of all respondents reporting that they had
missed doses in the last 14 days or yesterday on
Morisky-8 and reporting no missed doses on DAMS. In
all three cases where respondents reported that they had
not taken their medication yesterday (on the Morisky-8)
but had not missed any doses (on the DAMS) the medi-
cation had not been prescribed to be taken on the previ-
ous day, either because it was a weekly medication or
because the course had been completed. Only six
respondents had missed doses in the last 14 days (Mor-
isky-8) but had not missed any in the last seven days
(DAMS) and in four of these cases, the respondent was
able to offer a reason for the difference in adherence.
Whilst most of the differences between the Morisky-8
and DAMS could be explained by time period some
other factors were observed. Four high adherers on
Morisky-8 reported missed doses on DAMS. In two
cases this could be explained by the fact that Morisky-8
asks about ‘your medication’ rather than ‘all your medi-
cation’ so respondents said that they had taken their
medication the previous day even though they had
missed some of their medication(s). The time at which
medication had been taken was another cause of differ-
ence in reported adherence, with some patients taking
their medication at a later time (which is usually not
critical for effectiveness) and reporting this on either
scale as a missed or forgotten dose.
Lu is compared to DAMS in three ways, according to
the reporting method.
Lu frequency vs DAMS: Eight of the one hundred
respondents reported being fully adherent on the DAMS
but taking their medication less than all the time in theLow adherence
Medium adherence
High adherence
asure
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reported missing doses on DAMS but taking their
medication all the time in the last seven days on Lu.
Four of these discrepancies could be explained. In two
of the ten cases where there were discrepancies these
were due to patients taking ‘when required’ medication.
The LU does not distinguish between different medi-
cines and therefore patients on a mixture of ‘when
required’ and regular medicine did not state that they
had taken all their medication all the time if they had
only taken the ‘when required’ medicine occasionally.
In one case a respondent had only just been prescribed
the medication so had not taken it all the time in the
last seven days but had not missed a dose and one re-
spondent had insufficient English to understand the fre-
quency question.
Lu percentage vs DAMS: Eight (8%) respondents
reported being fully adherent on the DAMS but being
able to take their medication less than 100% of the time
exactly as their doctors had prescribed according to Lu.
In five cases this was due to incorrect timing and in one
case the respondent had only been prescribed the medi-
cation from the day before. In two cases there was no
explanation for the discrepancy. Four respondents
reported missing doses on the DAMS but taking their
medication as prescribed 100% of the time on the Lu. In
two cases the discrepancy was due to timing errors and
in one case the patient had missed doses when he had
wanted to drink alcohol on Saturday but his doctor had
said it was ok to miss doses in these circumstances so he
had in essence still taken his medication as his doctor
had prescribed 100% of the time. In the fourth case no
explanation was given.
Lu rating vs DAMS: In 24/100 cases respondents rated
their ability to take their medication as less than excel-
lent but reported missing no doses according to the
DAMS and in only six cases respondents rated their
ability as excellent but reported that they had missed
doses. This is an interesting finding as Lu et al found
that the rating question more closely resembled ‘object-
ive’ measures than the frequency and percentage mea-
sures. It is not clear why patients rate their ability to
take medication lower than their actual medication be-
haviour and an explanation was only offered by five
(19%) respondents. For example one respondent had
not missed any doses but rated his ability as good be-
cause he finds inhaler technique difficult. However, as
noted above this question was thought to be unclear by
many respondents and it also emerged that different
respondents interpreted the question differently. The
rating question is asking for a value judgement rather
than actual medication taking behaviour and respon-
dents may avoid extremes and rating themselves as
excellent.Limitations
Several limitations need to be acknowledged. This study
has focused on establishing face and content validity of
the DAMS and preliminary construct validity when
compared to other self report measures. However, fur-
ther testing is needed to establish validity against other
measures, such as the Medication Event Monitoring Sys-
tem (MEMS) , where the medication lid contains a
microchip which records every opening of the medicine
container. Further validation of the DAMS is underway
including the use of the DAMS in a large clinical trial.
In addition, reliability of the DAMs needs to be
established.
We changed the time period over which adherence
was measured in the Lu questionnaire. Whilst this may
have affected the psychometric properties of the Lu
scale, we were not using it as a gold standard measure
here. Rather, we wished to explore differences between
different question types and response options; and the
Lu questionnaire with the three different response
options was a useful comparator.
The comparison of patient medication records against
self reported medication history on the DAMS could
only be established in a small number of patients
(n = 16), which was a limitation to this part of the
analysis.
We recruited patients who were attending appoint-
ments at the primary care practice which meant that
housebound patients needing home visits would not
have been included in this study. However face and con-
tent validity of the DAMS has previously been estab-
lished in a population of patients using a pharmacy
service designed for people with adherence problems,
many of whom were housebound.
Conclusion
Adherence levels captured by the three different adher-
ence instruments are in agreement when measuring
patients’ medication taking behaviour in a primary care
population of patients attending general practice. All
struggled with ‘as required’ medication which we think
should be excluded from these measures. On further
analysis, differences in trends between the DAMS and
the other two adherence measures could mostly be
explained by qualitative data, although the Lu rating
question needs further clarification. The association of
the DAMS with two validated adherence instruments
provides some validation for the new instrument. The
DAMS was developed specifically to meet the criteria
for routinely monitoring adherence in clinical practice,
as well as supporting the development and evaluation of
adherence enhancing interventions. It was able to meas-
ure type and extent of non-adherence thereby aiding in
the identification of appropriate interventions and
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http://www.biomedcentral.com/1472-6963/12/350measuring change in adherence over time; it also has the
advantage of having a carers’ version. In summary, the
DAMS has now been tested in a range of populations in-
cluding housebound patients, patients attending general
practice appointments and a secondary care population.
Further tests of the DAMS against objective measures
such as MEMS are in progress and reliability needs to
be established. Testing of the carers’ version of the
DAMS is at the preliminary stage and further investiga-
tion is required.
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